HMHans K. Meier-Ewert

Hans K. Meier-Ewert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans K. Meier-Ewert has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increasing sleep duration to lower beat‐to‐beat blood pressure: a pilot study

    by Monika Haack, Jorge Serrador, Daniel Cohen, Norah Simpson, Hans Meier‐Ewert, Janet M. Mullington

    Summary: Strong evidence has accumulated over the last several years, showing that low sleep quantity and/or quality plays an important role in the elevation of blood pressure. We hypothesized that increasing sleep duration serves as an effective behavioral strategy to reduce blood pressure in prehypertension or type 1 hypertension. Twenty‐two participants with prehypertension or stage 1 hypertension, and habitual sleep durations of 7 h or less, participated in a 6‐week intervention study. Subjects were randomized to a sleep extension group (48 ± 12 years, N = 13) aiming to increase bedtime by 1 h daily over a 6‐week intervention period, or to a sleep maintenance group (47 ± 12 years, N = 9) aiming to maintain habitual bedtimes. Both groups received sleep hygiene instructions. Beat‐to‐beat blood pressure was monitored over 24 h, and 24‐h urine and a fasting blood sample were collected pre‐ and post‐intervention. Subjects in the sleep extension group increased their actigraphy‐assessed daily sleep duration by 35 ± 9 min, while subjects in the sleep maintenance condition increased slightly by 4 ± 9 min (P = 0.03 for group effect). Systolic and diastolic beat‐to‐beat blood pressure averaged across the 24‐h recording period significantly decreased from pre‐ to post‐intervention visit in the sleep extension group by 14 ± 3 and 8 ± 3 mmHg, respectively (P < 0.05). Though the reduction of 7 ± 5 and 3 ± 4 mmHg in the sleep maintenance group was not significant, it did not differ from the blood pressure reduction in the sleep extension group (P = 0.15 for interaction effect). These changes were not paralleled by pre‐ to post‐intervention changes in inflammatory or sympatho‐adrenal markers, nor by changes in caloric intake. While these preliminary findings have to be interpreted with caution due to the small sample size, they encourage future investigations to test whether behavioral interventions designed to increase sleep duration serve as an effective strategy in the treatment of hypertension.


  • High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

    by Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, et al.


  • Sleep inflammation and cardiovascular disease

    by Hans K. Meier-Ewert, David E. Solarz, Janet M. Mullington

    In data from prospective cohort studies, self report of insufficient or disturbed sleep is related to increased overall and cardiovascular morbidity. Inflammation is established as a key mechanism in the development of arteriosclerotic heart and vascular disease. Inflammation has been considered a possible link between short sleep and cardiovascular disease and morbidity. Measures of inflammation are increased by experimental sleep deprivation, but in cohort studies a relationship of sleep duration to inflammatory markers is less clear. In these studies the association of self reported short sleep to cardiac morbidity is confounded by many psychological and socioeconomic variables. More studies are needed to explain the link between short sleep duration and cardiac morbidity. Experimental studies of sleep deprivation mimicking habitual shortened sleep over long time intervals, and studies employing sleep extension in habitual short sleepers will allow better characterization of the health benefits of adequate sleep duration. Prospective cohort studies should include objective measures of sleep duration and should to control for the known confounding variables.


  • Open Access

    Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

    by Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, et al.

    Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete response (CR). We analyzed a series of 421 consecutive patients treated with HDM/SCT at a single referral center and compared outcomes for patients with and without CR. Treatment-related mortality was 11.4% overall (5.6% in the last 5 years). By intention-to-treat analysis, the CR rate was 34% and the median event-free survival (EFS) and overall survival (OS) were 2.6 and 6.3 years, respectively. Eighty-one patients died within the first year after HDM/SCT and were not evaluable for hematologic and organ response. Of 340 evaluable patients, 43% achieved CR and 78% of them experienced an organ response. For CR patients, median EFS and OS were 8.3 and 13.2 years, respectively. Among the 195 patients who did not obtain CR, 52% achieved an organ response, and their median EFS and OS were 2 and 5.9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR.


  • Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management

    by Hans K. Meier-Ewert, Vaishali Sanchorawala, John L. Berk, Frederick L. Ruberg

    The systemic amyloidoses are a group of heterogeneous disorders characterized by extracellular deposition of misfolded fibrillar protein that results in organ dysfunction. Involvement of the heart (cardiac amyloidosis) is manifest by increased cardiac wall thickness and impairment of myocardial diastolic and systolic properties, changes that result in heart failure, dysrhythmia, and death. Amyloidosis is classified by precursor protein, with light-chain (AL) and transthyretin (TTR) disease being most common in the United States. TTR amyloid can result from misfolding of variant TTR, a genetically inherited disease, or wild-type TTR, an acquired form of disease (termed senile systemic amyloidosis). In recent years, advances in the diagnosis and treatment of cardiac amyloidosis include identification and validation of disease biomarkers, new imaging techniques, and consensus treatment guidelines. Elevations of B-type natriuretic peptide and cardiac troponins can identify cardiac amyloidosis with a high degree of precision and confer important prognostic information. Non-invasive cardiac imaging techniques, such as cardiac magnetic resonance imaging and echocardiography with strain quantification, afford the ability to diagnose cardiac amyloidosis most often without the need for a confirmatory heart biopsy. Treatment of heart failure resulting from cardiac amyloidosis differs in many respects from most other etiologies of cardiomyopathy. The mainstay of treatment involves volume control with diuretics, low dose β-adrenergic antagonists or amiodarone for dysrhythmia, and warfarin to prevent thromboembolism. Although widely held to have a dismal prognosis, modern treatments such as high-dose melphalan with stem cell transplantation (HDM/SCT) for AL disease achieve a complete hematologic response in nearly half of eligible patients and yield long-term survival. For patients with advanced AL cardiac amyloidosis, cardiac transplantation followed by HDM/SCT is also an option that has proven highly effective. For familial amyloid derived from variant TTR, liver transplantation is the one validated treatment; however, small molecule therapeutic agents now in clinical trials appear capable of slowing or halting TTR amyloid deposition.


  • Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis

    by H. K. Meier-Ewert, V. Sanchorawala, J. Berk, K. T. Finn, M. Skinner, D. C. Seldin, F. L. Ruberg

    (2011). Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid: Vol. 18, No. sup1, pp. 130-131. doi: 10.3109/13506129.2011.574354048


  • High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution

    by D. C. Seldin, N. Andrea, I. Berenbaum, J. L. Berk, L. Connors, L. M. Dember, G. Doros, S. Fennessey, K. Finn, S. Girnius, et al.

    Due to late diagnosis, vital organ failure is common in AL amyloidosis. This may delay or prevent crucial therapeutic approaches aimed at eradicating the plasma cell clone, such as high-dose chemotherapy and autologous stem cell transplantation. Solid organ transplantation to overcome organ failure is controversial due to both the shortage of organs and the systemic nature of the disease and the likely recurrence in the graft. We report on a patient who underwent liver transplantation while in hematologic remission after autologous stem cell transplantation. The issue of solid organ transplantation in AL amyloidosis and the role of the new drugs are briefly discussed. © 2011 Informa UK, Ltd


  • Sleep loss and inflammation

    by Janet M. Mullington, Norah S. Simpson, Hans K. Meier-Ewert, Monika Haack